The price of prescribed drugs by the pharmaceuticals is quite high. The consequences are so because Pharmaceuticals Company says that the discovery and making of drugs are very expensive and risky at the same time. But this is becoming an issue for the healthcare sectors and things will only get worse if not solved.
Pharmaceuticals are the not the one that’ leading the problems in the health care sectors but the rising prices of the pharmaceutical drugs are the reflection of the problems that are being faced by the health care segments due to affordability issues and thus the entire health group gets affected. Thus controlling price will never bring any better changes until implemented, only then the roots of the problem will be transparent from itself.
Reforms in the pricing system of pharmaceutical drugs are massively necessary as controlling price is not the ultimate solution. Lately selling of the pharmaceuticals products passes through a critical chain, where the interest of the consumers is not running the market, and the complex chain of bureaucratic rules and rebates conceal the necessary information on prices that are supposed to be out.
Thus, checking and correction of the price issue is the best way for improving the health care segment as well as the patients.
The involvement of Government and law makers in this field of price issue can connect to the main problem and thus solve the issue. The price negotiation of the prescription-drugs by the federal Government and pursuing further more incremental policies by the law makers can make it better to a great extent.
The price discounts are paid after selling the medicine thus the original price of the medicine remains unknown to the patients when received from the pharmacy. Furthermore, rebates are a common fact in other markets that are given to the consumers. But the pharmaceutical markets work otherwise. Here the maximum share of rebates gets lost to the PBMs quite often. As a result of which the PBMs are triggered to encourage the adding of the high price in the medicine lists then negotiates maximum rebates for the insurance companies and bag a large share of them. So, it is clear that they necessarily not need to charge massive price.